• Surgical Oncology Insight Banner Ad x

ADVERTISEMENT

Global Header

Annals of Surgical Oncology

HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY

Weekly Update

Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis

May 16, 2024

Citation: Sugumar, K., Stitzel, H., Wu, V. et al. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15187-y
Synopsis: This meta-analysis shows that hepatic artery infusion and multiagent chemotherapy are effective therapies in unresectable colorectal liver metastasis. Though triplet chemotherapy appeared to outperform other arms, high toxicity and inclusion of potentially resectable patients must be considered while interpreting results.

Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland

May 16, 2024

Citation: Putila, E., Helminen, O., Helmiö, M. et al. Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland. Ann Surg Oncol 31, 2689–2698 (2024). https://doi.org/10.1245/s10434-023-14813-5
Synopsis: This study compares postoperative complications between neoadjuvant chemotherapy and upfront surgery after gastrectomy for gastric adenocarcinoma in a population-based setting (n=1769). Neoadjuvant chemotherapy did not increase major postoperative complications after gastrectomy for gastric cancer compared to upfront surgery (OR 1.12, 95% CI 0.81-1.56). Furthermore, it did not increase reoperations or short-term mortality compared to upfront surgery.

Listen to the ASO's podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who expands upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Instagram. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

twitter icon instagram icon

Scroll to Top